Third Quarter 2021

Earnings Highlights

$24.1B
Q3 Revenue
+130%
Op Growth[1]

Q3 EPS

$1.42	$1.34
Rep. Dil. EPS	Adj. Dil. EPS[2]
+446% Op Growth	+129% Growth

Q3 R&D Expenses

$3.4B	$2.7B
Rep. R&D Expenses	Adj. R&D Expenses[2]
+49% Op Growth	+19% Op Growth

~2.3B
COVID-19 Vaccines
expected to be delivered by YE 2021

3.5%[3]
Dividend Yield
12 consecutive years of dividend increases

Raised
FY 2021 Guidance[4]
Rev. $81B–$82B
Adj. Dil. EPS[2] $4.13–$4.18

"Our ultimate goal is to help bring this pandemic to an end as quickly as possible, but also to apply the lessons we have learned through our work on the vaccine to all of our therapeutic areas."

Albert Bourla
Chairman and Chief Executive Officer

Key Growth Drivers[5]

- Pfizer-BioNTech COVID-19 vaccine — $12,977M Revenue
- Eliquis apixaban — $1,346M Revenue, +19% Op Growth
- IBRANCE palbociclib — $1,381M Revenue, +1% Op Growth, +9% Int'l Op Growth
- Vyndamax (tafamidis) — $501M Revenue[6], +42% Op Growth
- Xtandi (enzalutamide) — $309M Revenue, +16% Op Growth
- Inlyta axitinib — $256M Revenue, +30% Op Growth
- Hospital Products — $2,367M Revenue, +29% Op Growth
- Oncology Biosimilars — $398M Revenue, +51% Op Growth

Pipeline Spotlights

- Pfizer-BioNTech COVID-19 vaccine — First U.S. emergency use authorization granted for children 5-11
- Candidate COVID-19 Protease Inhibitor — Initiation of Phase 2/3 studies for IV and oral therapy
- Candidate ritlecitinib — Successful Phase 2b/3 trial to treat alopecia areata
- Candidate RSVAdult vaccine — First patient dosed in Phase 3 human trial
- Proposed Acquisition TRILLIUM THERAPEUTICS INC. — Entered agreement to acquire next-generation immuno-therapeutics company
- Approved Pfizer-BioNTech COVID-19 vaccine — First COVID-19 vaccine to receive U.S. FDA approval (Comirnaty brand name)
- Approved (in Great Britain & Japan) CIBINQO (abrocitinib) tablets — Treatment of moderate to severe atopic dermatitis in adults and adolescents
- Approved TicoVac Tick-Borne Encephalitis Vaccine — First U.S. vaccine to protect adults and children from tick-borne encephalitis

Vaccines · Internal Medicine · Inflammation/Immunology · Oncology · Rare Disease · Hospital

946M
patients reached
worldwide YTD with our medicines and vaccines[7]

Strong Portfolio Progression

Anticipated in the Next 18 Months

- Up to **10** Potential Approvals[8]
- Up to **15** Projected Pivotal Readouts[8]
- Up to **15** Potential Proof of Concept Readouts

What's Next

Reaffirm projected revenue CAGR of at least 6% and double-digit adjusted diluted EPS[2] growth through 2025[9]

- **Maintain** patient centricity
- **Scale** emerging tech platforms
- **Invest** in areas we can win
- **Foster** a culture of innovation
- **Reduce** approval development cycle times

25 BY 2025
Ambition of up to 25 breakthrough launches in patients' hands by 2025
~$35B to $40B in non-risk-adjusted peak sales potential



investors.pfizer.com

Please reference Pfizer's Q3 2021 earnings release and SEC filings for additional information.

[1] Operational revenue growth. Reference to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates.
[2] Adjusted income and its components and Adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items. Adjusted research and development (R&D) expenses is an income statement line item prepared on the same basis as, and therefore a component of, the overall Adjusted income measure. As described in the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2020 Annual Report on Form 10-K, management uses Adjusted income, among other factors, as an important internal performance measure, which management believes enhances Pfizer's investors' understanding of our performance. Pfizer reports Adjusted income, certain components of Adjusted income, and Adjusted diluted EPS in order to present the results of the company's major operations prior to considering certain income statement elements. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the third quarter of 2021 and 2020 in Pfizer's earnings release furnished with Pfizer's Current Report on Form 8-K dated November 2, 2021. The Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS, have no standardized meaning prescribed by U.S. GAAP and may not be comparable to the calculation of similar measures of other companies.
[3] Annualized dividend based on Volume Weighted Average Price (VWAP) from July 6, 2021 to October 1, 2021, per Bloomberg.
[4] Total company guidance.
[5] Q3 financial performance.
[6] Presented figures include sales of both Vyndaqel and Vyndamax.
[7] Patient counts are estimates derived from multiple data sources.
[8] Reference the full set of materials and/or the Appendix section of Q3 2021 Earnings Presentation for list of potential approvals and projected pivotal and proof of concept readouts.
[9] Excludes the impact of Pfizer-BioNTech COVID-19 vaccine (Comirnaty), recent or subsequent BD activities or potential future mRNA programs.

This document includes forward-looking statements about, among other things, Pfizer's anticipated operating and financial performance, product pipeline, in-line products and product candidates, business plans and prospects, manufacturing and product supply and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2020, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this document. These reports are available on Pfizer's website at www.pfizer.com and on the U.S. Securities and Exchange Commission's website at www.sec.gov. The forward-looking statements in this document speak only as of the original date of this document, and we undertake no obligation to update or revise any of these statements.